KDIGO-defined kidney dysfunction predicts long-term outcomes in a multicenter cohort of adults with sickle cell disease
Approximately 15% of deaths in adults with sickle cell disease (SCD) are attributed to kidney failure. Although urine albumin-to-creatinine ratio (UACR) is recommended to screen for kidney damage, its utility in predicting long-term complications in SCD remains unclear. We investigated whether "Kidney Disease: Improving Global Outcomes (KDIGO)" algorithms used to assess kidney disease in the general population predicted chronic kidney disease (CKD) progression and mortality in a longitudinal cohort of 379 adults with SCD from 2 academic institutions. KDIGO criteria include UACR detected in 2 consecutive measurements ≥3 months apart and a heat map integrating UACR with estimated glomerular filtration rate. KDIGO-defined CKD was present in 39.8% of individuals in our SCD cohort. Over a median follow-up of 3.3 years, incremental KDIGO-defined UACR category independently predicted a twofold greater risk of CKD progression and 1.8-fold greater risk of mortality (P ≤ .05). KDIGO-defined CKD heat map strengthened the ability to predict CKD progression and mortality risk (P ≤ .0087). Our data provide clinical support for the screening utility of UACR based on repeated abnormal values ≥3 months apart. The KDIGO heat map further refines the risk of long-term outcomes among adults with SCD and should be applied to guide future studies for monitoring and intervention strategies.
Authors
- Rima S. Zahr (ORCID: https://orcid.org/0000-0002-3631-7195)
- Victor R. Gordeuk (ORCID: https://orcid.org/0000-0003-4725-7295)
- Kristin Wuichet (ORCID: https://orcid.org/0000-0002-5653-2597)
- Santosh L. Saraf (ORCID: https://orcid.org/0000-0002-8584-4194)
- Michael R. DeBaun (ORCID: https://orcid.org/0000-0002-0574-1604)
- Mitchell J. Weiss (ORCID: https://orcid.org/0000-0003-2460-3036)
- Zalaya Ivy (ORCID: https://orcid.org/0000-0002-3185-1786)
- Xu Zhang (ORCID: https://orcid.org/0000-0003-2707-8927)
- Alexander G. Bick
Institutions
- St. Jude Children's Research Hospital (US)
- University of Tennessee Health Science Center (US)
- Vanderbilt University (US)
- University of Illinois Chicago (US)
- University of Chicago (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Blood Advances
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1182/bloodadvances.2025017204
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Vertex Pharmaceuticals
- Agios Pharmaceuticals
- bluebird bio
- Incyte
- Novo Nordisk
- National Institutes of Health